Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Rating of "Hold" by Analysts

Key Points

• Zimmer Biomet Holdings, Inc. has received an average rating of "Hold" from 21 research firms, with recommendations varying from sell to strong buy.
• The company recently posted a quarterly revenue increase of 7.0% year-over-year, achieving earnings of $2.07 per share, surpassing analyst expectations.
• Zimmer Biomet announced a quarterly dividend of $0.24 per share, translating to an annualized yield of 1.0%.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) have been assigned an average recommendation of "Hold" from the twenty-one research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $112.4444.

ZBH has been the topic of a number of analyst reports. Evercore ISI decreased their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Rothschild Redb raised Zimmer Biomet to a "strong-buy" rating in a report on Thursday, September 18th. Royal Bank Of Canada increased their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a "buy" rating in a research note on Friday, September 19th. Finally, Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th.

Zimmer Biomet Trading Down 1.9%

Shares of ZBH stock opened at $98.88 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The firm has a market cap of $19.59 billion, a P/E ratio of 24.06, a PEG ratio of 2.32 and a beta of 0.67. The company has a 50 day moving average of $100.93 and a 200-day moving average of $98.54. Zimmer Biomet has a 12-month low of $89.22 and a 12-month high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the business earned $2.01 earnings per share. The company's quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. lifted its position in Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. Dodge & Cox raised its position in shares of Zimmer Biomet by 12.9% during the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider's stock valued at $2,015,510,000 after buying an additional 2,533,009 shares in the last quarter. Norges Bank bought a new stake in shares of Zimmer Biomet during the 2nd quarter worth $225,867,000. JPMorgan Chase & Co. grew its position in Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after acquiring an additional 1,488,918 shares in the last quarter. Finally, Nuveen LLC bought a new position in Zimmer Biomet in the first quarter valued at $155,891,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.